ProKidney Corp (NASDAQ:PROK) is highlighted as one of the best healthcare penny stocks to buy now. The company is focused on cell therapy, Reparencel, which is showing promising results. ProKidney anticipates top-line results from the Proactive One study by Q2 2027, targeting high-risk chronic kidney disease patients with a GFR of 30 or less. The company is financially strong with $295 million in cash as of June and is expanding its manufacturing capacity in North Carolina to meet anticipated demand for its therapy.

Read more at Yahoo Finance: ProKidney Corp (PROK) Touts Reparencel Therapy for Growth